France's Sanofi buys US hemophilia specialist Bioverativ
France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases.
Monday, January 22, 2018
France's Sanofi buys US hemophilia specialist Bioverativ
France's Sanofi buys US hemophilia specialist Bioverativ
France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases.
Related Posts:
Daimler: CEO Zetsche to be succeeded by development head- Nissan blames latest improper tests on 'low awareness' of rules
- Against trade war, Fed backdrop China sets positive world equity tone
- Anbang in talks to sell Japan real estate to Blackstone, other bidders: sources
- Brexit at breaking point? Diary dates for Britain's EU departure
0 comments:
Post a Comment